Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Spanish reimbursement system

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

- PMLiVE

Arthritis patient group launches interactive video initiative

NRAS hopes its Love Your Heart programme will lower CV risks in those with RA

- PMLiVE

Love Your Heart: An Innovative Interactive Video Programme

NRAS Launches 'Love Your Heart' Interactive Video Programme. A new initiative aims to decrease cardiovascular risk for people with Rheumatoid Arthritis.

Streaming Well

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

- PMLiVE

Trio of new starters for Wave

Lucy Noble, Ella Withey and Maria Cain join the UK med ed agency

- PMLiVE

McCann Health appoints Daniel Carucci as global medical director

The newly-created position will see him work across McCann's global network

Finding the patient voice

How patients feel and speak about clinical trials

Six Degrees Medical

Six Degrees Medical Consulting

- PMLiVE

Another Alzheimer’s bust as Merck & Co stops verubecestat study

Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

- PMLiVE

Vertex’s two-drug cystic fibrosis treatment cleared in US

FDA approves Symdeko, which combines Kalydeco and tezacaftor

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links